- Home
- ALLR vs CLRB Comparison
ALLR vs CLRB Comparison
Compare ALLR & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLR
- CLRB
- Stock Information
- Founded
- ALLR 2004
- CLRB 2002
- Country
- ALLR United States
- CLRB United States
- Employees
- ALLR N/A
- CLRB N/A
- Industry
- ALLR Biotechnology: Pharmaceutical Preparations
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- ALLR Health Care
- CLRB Health Care
- Exchange
- ALLR Nasdaq
- CLRB Nasdaq
- Market Cap
- ALLR 15.8M
- CLRB 14.2M
- IPO Year
- ALLR N/A
- CLRB N/A
- Fundamental
- Price
- ALLR $1.01
- CLRB $4.72
- Analyst Decision
- ALLR Strong Buy
- CLRB Hold
- Analyst Count
- ALLR 1
- CLRB 2
- Target Price
- ALLR $9.00
- CLRB N/A
- AVG Volume (30 Days)
- ALLR 536.3K
- CLRB 121.3K
- Earning Date
- ALLR 08-08-2025
- CLRB 08-12-2025
- Dividend Yield
- ALLR N/A
- CLRB N/A
- EPS Growth
- ALLR N/A
- CLRB N/A
- EPS
- ALLR N/A
- CLRB N/A
- Revenue
- ALLR N/A
- CLRB N/A
- Revenue This Year
- ALLR N/A
- CLRB N/A
- Revenue Next Year
- ALLR N/A
- CLRB N/A
- P/E Ratio
- ALLR N/A
- CLRB N/A
- Revenue Growth
- ALLR N/A
- CLRB N/A
- 52 Week Low
- ALLR $0.61
- CLRB $4.36
- 52 Week High
- ALLR $6.00
- CLRB $68.70
- Technical
- Relative Strength Index (RSI)
- ALLR 49.17
- CLRB 36.75
- Support Level
- ALLR $1.03
- CLRB $4.65
- Resistance Level
- ALLR $1.17
- CLRB $5.15
- Average True Range (ATR)
- ALLR 0.08
- CLRB 0.39
- MACD
- ALLR -0.00
- CLRB 0.12
- Stochastic Oscillator
- ALLR 28.89
- CLRB 19.82
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.